Generic form of mesalamine approved
The drug is indicated to induce remission in adults with active, mild to moderate ulcerative colitis and to maintain remission of ulcerative colitis.
On June 5, the FDA approved the first generic form of mesalamine delayed-release oral tablets USP (1.2 g). The drug is indicated to induce remission in adults with active, mild to moderate ulcerative colitis and to maintain remission of ulcerative colitis. Brand names include Lialda.